CALCIUM-ANTAGONISTS PREVENT MONOCYTE AND ENDOTHELIAL CELL-INDUCED MODIFICATION OF LOW-DENSITY LIPOPROTEINS

被引:29
作者
BREUGNOT, C
MAZIERE, C
AUCLAIR, M
MORA, L
RONVEAUX, MF
SALMON, S
SANTUS, R
MORLIERE, P
LENAERS, A
MAZIERE, JC
机构
[1] UNIV PARIS 06, BIOCHIM LAB, 27 RUE CHALIGNY, F-75571 PARIS 12, FRANCE
[2] INST RECH SERVIER, F-92200 SURESNES, FRANCE
[3] MUSEUM NATL HIST NAT, PHYSICOCHIM ADAPTAT BIOL LAB, INSERM, U312, F-75231 PARIS 05, FRANCE
[4] FAC UNIV NOTRE DAME PAIX, UNITE CYTOL, B-5000 NAMUR, BELGIUM
[5] HOP HENRI MONDOR, RECH & DERMATOL LAB, F-94010 CRETEIL, FRANCE
来源
FREE RADICAL RESEARCH COMMUNICATIONS | 1991年 / 15卷 / 02期
关键词
CALCIUM ANTAGONISTS; LDL PEROXIDATION;
D O I
10.3109/10715769109049129
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Low density lipoprotein (LDL) incubated in the presence of the calcium antagonists verapamil, nifedipine and flunarizine were more resistant than control LDL to human monocyte- or endothelial cell-induced modification, as assessed by electrophoretic mobility in agarose gel, thiobarbituric acid reactive substance content, and degradation by J774 macrophages. The efficiency of the drugs was: flunarizine > nifedipine > veraparml. Moreover, a 24 h preculture with calcium antagonists significantly impaired the ability of cells to modify LDL in the absence of the drugs. All the studied drugs also inhibited copper-induced autooxidation of LDL. None of the studied calcium antagonists, at concentrations up to 10-4 M, significantly reacted with free radicals as assessed by the l,1-diphenyl-2-picrylhydrazyl test. It is suggested that such a protective effect of calcium antagonists against LDL peroxidation could play a role in the previously reported antiatherogenic effect of these drugs. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:91 / 100
页数:10
相关论文
共 35 条
  • [1] METABOLISM OF VERY LOW-DENSITY LIPOPROTEIN PROTEINS .1. PRELIMINARY IN-VITRO AND IN-VIVO OBSERVATIONS
    BILHEIMER, DW
    LEVY, RI
    EISENBERG, S
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1972, 260 (02) : 212 - +
  • [2] ANTIOXIDANT DETERMINATIONS BY THE USE OF A STABLE FREE RADICAL
    BLOIS, MS
    [J]. NATURE, 1958, 181 (4617) : 1199 - 1200
  • [3] BOYD HC, 1989, AM J PATHOL, V135, P815
  • [4] PHENOTHIAZINES INHIBIT COPPER AND ENDOTHELIAL CELL-INDUCED PEROXIDATION OF LOW-DENSITY-LIPOPROTEIN - A COMPARATIVE-STUDY WITH PROBUCOL, BUTYLATED HYDROXYTOLUENE AND VITAMIN-E
    BREUGNOT, C
    MAZIERE, C
    SALMON, S
    AUCLAIR, M
    SANTUS, R
    MORLIERE, P
    LENAERS, A
    MAZIERE, JC
    [J]. BIOCHEMICAL PHARMACOLOGY, 1990, 40 (09) : 1975 - 1980
  • [5] REGULATION OF PLASMA-CHOLESTEROL BY LIPOPROTEIN RECEPTORS
    BROWN, MS
    KOVANEN, PT
    GOLDSTEIN, JL
    [J]. SCIENCE, 1981, 212 (4495) : 628 - 635
  • [6] RECEPTOR-MEDIATED CONTROL OF CHOLESTEROL-METABOLISM
    BROWN, MS
    GOLDSTEIN, JL
    [J]. SCIENCE, 1976, 191 (4223) : 150 - 154
  • [7] THE EFFECTS OF PERHEXILINE-MALEATE ON LOW-DENSITY LIPOPROTEIN PROCESSING AND CHOLESTEROL-METABOLISM IN CULTURED HUMAN-FIBROBLASTS
    CANDIDE, C
    MAZIERE, JC
    MAZIERE, C
    LAGERON, A
    POLONOVSKI, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (02) : 195 - 199
  • [8] MONOCYTES AND NEUTROPHILS OXIDIZE LOW-DENSITY LIPOPROTEIN MAKING IT CYTO-TOXIC
    CATHCART, MK
    MOREL, DW
    CHISOLM, GM
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 1985, 38 (02) : 341 - 350
  • [9] VERAPAMIL ENHANCES HIGH-DENSITY-LIPOPROTEIN PROCESSING IN HEP G2 CELLS PRELOADED WITH CHOLESTEROL
    CHAPPEYGILLET, B
    SALMON, S
    MAZIERE, C
    AUCLAIR, M
    MAZIERE, JC
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1052 (02) : 273 - 277
  • [10] CORSINI A, 1986, PHARMACOL RES, V18, P1